Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives

Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives

See the new book, edited by Neelesh Kumar Mehra. The aim of the proposed book is to provide exhaustive information about the fundamental concepts, theory and applications of the simple and complex ophthalmic dosage forms with emphasis on the regulatory aspects of the same for formulators and academic / industrial researchers.

Description: The proposed book comprehensively covers the current research trends and industrial inputs beginning from the pharmaceutical product development strategy, composition, labelling, challenges, NDA vs ANDA filing to the advanced drug delivery approaches using novel micro and nanocarriers, fixed–dose combinations, role of preservatives in product development and so on. This book also covers various eye related disease like glaucoma, age-related macular degeneration, uveal melanoma, cataract, fungal keratitis, conjunctivitis, blindness etc. which need to be treatable.

The sterile ophthalmic product development approaches inclusive of different drug delivery dosage form technologies have been revolutionary in current healthcare, pharmaceutical research and innovation. However, it has its own challenges in scale up and commercial aspects, which could be a reason for limited scope and availability of ophthalmic products in market. Development of complex sterile ophthalmic product is crucial and needs proper systematic approaches starting from pre-formulation till validation, scale up and commercialization including toxicological data. This book presents these approaches in vivid chapters contributed by renowned formulators, researchers and academician working in the fields of ophthalmic product development across the world.

The primary audience for the proposed book would be academic and industrial researchers, PhD/postdoctoral research fellows, formulation scientists and bio-medical professionals. The comprehensive focus on fundamental concepts, advanced drug formulation and regulatory guidelines will benefit students as well as professionals in the field of ophthalmic medicine.

Chapter 1

Ocular Drug Delivery: Introduction and Fundamental Concept

Ocular diseases are one of the most serious concerns worldwide, with more than 45 million cases of blindness, significantly affecting the vision and quality of life of the patients. However, effective drug delivery to the eyes remains challenging, especially to the posterior region of the eye due to the presence of various ocular barriers. This led to various advancements in the development of various novel ocular therapeutics with superior efficacy and safety. This chapter highlights the basics of ocular drug delivery systems (ODDS) including the anatomy of the eyes and their physiological barriers affecting the drug delivery, various invasive and noninvasive routes of ocular drug administration, a brief overview of ocular diseases, their complications, and various conventional and novel ODDS. Regulatory perspectives of ODDS, overview of marketed ophthalmic products, and recently approved patents along with the future perspectives in design and development of safe and effective ODDS have also been addressed in this chapter.

See the chapter

Khan, O. et al. (2025). Ocular Drug Delivery: Introduction and Fundamental Concept. In: Mehra, N.K. (eds) Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives. Springer, Singapore. https://doi.org/10.1007/978-981-96-6306-4_1

Chapter 3

Drug Delivery to the Anterior Segment of Eye

The human eye’s complex anatomy and protective barriers pose significant challenges for effective drug delivery, with conventional methods like eye drops exhibiting low bioavailability (<5%) and transient therapeutic effects. This chapter examines recent advancements in ocular drug delivery systems designed to overcome these limitations, focusing on minimally invasive strategies for anterior segment disorders. Innovations such as long-acting biodegradable and nonbiodegradable implants (e.g., Ozurdex®, Durysta®) enable sustained drug release, reducing administration frequency and enhancing compliance. Electrospun nanofiber patches and particulate systems (liposomes, nanoparticles) improve corneal penetration and retention, while microneedle technology offers precise, painless delivery of biologics and small molecules. Drug-eluting contact lenses integrate therapeutic release with vision correction, leveraging stimuli-responsive materials for controlled delivery. Despite their promise, challenges persist in scalability, regulatory compliance, and clinical translation. Future directions emphasize smart materials, combination therapies, and personalized approaches to optimize efficacy and safety. Collectively, these technologies represent a paradigm shift in ocular therapeutics, addressing chronic conditions like glaucoma, uveitis, and dry eye syndrome with enhanced bioavailability and reduced patient burden. By bridging gaps between innovation and clinical application, these systems hold transformative potential for improving patient outcomes and quality of life in ocular healthcare.

See the chapter

Gade, S., Mishra, D., Yu, Z., Jiang, G., Vora, L.K., Thakur, R.R.S. (2025). Drug Delivery to the Anterior Segment of Eye. In: Mehra, N.K. (eds) Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives. Springer, Singapore. https://doi.org/10.1007/978-981-96-6306-4_3

Chapter 4

Drug Delivery to the Posterior Segment of Eye

Diseases associated with posterior segment of the eye like age-related maculopathy and diabetic retinopathy are prime reasons that extremely menace normal vision as well as healthy well-being, and their therapy is highly difficult for ophthalmologists, researchers, and specialists. Delivery of drugs for the treatment of posterior segment oculopathy using noninvasive procedures is the need of time; however, it is very challenging. Recently, several new topical systems have been formulated which are promising due to the improved patient compliance as the intervention of surgery or needles is negligible. This chapter primarily focuses on the different means of drug delivery for the therapy of conditions associated with the posterior segment of the eye. In the first part of this chapter, the anatomy of ocular posterior segment and the associated diseases are crisply discussed. Further, the biological ocular barriers that prevent the drug delivery are mentioned. Afterward, both invasive and noninvasive routes explored by the researchers for the therapy of posterior segment oculopathy are discussed. As a follow-up, new strategies in the delivery of therapeutics via the noninvasive route using different nanovehicles and contact lenses are extensively elaborated which also draws the conclusion that the potential of nanoformulations for the therapy of posterior oculopathy must be explored at the full extent with systematic and comprehensive efforts by researchers.

See the chapter

Tarannum, S., Jain, K. (2025). Drug Delivery to the Posterior Segment of Eye. In: Mehra, N.K. (eds) Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives. Springer, Singapore. https://doi.org/10.1007/978-981-96-6306-4_4

See the full book here

Neelesh Kumar Mehra, Complex Ophthalmic Dosage Forms: Advances in Biomedical Applications and Future Perspectives, Springer Singapore, DOI https://doi.org/10.1007/978-981-96-6306-4